Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 92%
filed 2026-06-23
Item 1.01
FiEE entered into an at-the-market (ATM) sales agreement with A.G.P./Alliance Global Partners on June 23, 2026, authorizing the issuance of up to $6.27 million in common stock shares. This is a classic dilutive equity issuance under an ATM program, which allows the company to raise capital by selling shares at market prices. The disclosure explicitly references the shelf registration statement (Form S-3) and prospectus supplement filed in connection with the offering, and the company retains discretion over timing and amount of sales. Such equity offerings are material to investors as they dilute existing shareholders and signal capital needs.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
Item 3.02
Ares Core Infrastructure Fund sold 34.1 million Common Shares across four classes for an aggregate purchase price of $851.3 million in a private placement exempt from Securities Act registration under Section 4(a)(2) and Regulation D Rule 506(b).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
Item 3.02
Golub Capital Private Income Fund S issued 71,086 common shares of beneficial interest for approximately $1.72 million in an unregistered sale exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
Item 3.02
The Fund sold 102,555 unregistered common shares of beneficial interest for $2,489,000 as of June 1, 2026, pursuant to subscription agreements and exempt from Securities Act registration under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-22
Item 1.01
HIVE amended and restated its Equity Distribution Agreement on June 16, 2026, authorizing the sale of up to US$300 million in common shares through an at-the-market offering, with $214.7 million in unused offering capacity as of the prospectus supplement filed June 17, 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Stone Point Credit Income Fund disclosed the unregistered sale of 1,013,220.501 common shares at NAV for $25,000,000 aggregate offering price, plus an additional 495,413.844 shares for $12,223,742, pursuant to subscription agreements with accredited investors under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive private placement of equity securities exempt from registration, material to investors assessing the Fund's capital structure and the dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Third Point Private Capital Partners completed an unregistered sale of 384,766 Class I common shares for $10,000,000 as of May 1, 2026, relying on Section 4(a)(2) and Regulations D and S exemptions to accredited investors and non-U.S. persons.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-22
Item 3.02
The Company issued 200,000 shares of Class B common stock to CEO/Chairman Huan Liu at $2.00 per share ($400,000 gross proceeds) in an unregistered private placement under Regulation S and Section 4(a)(2). The restricted securities issuance dilutes existing shareholders and represents a material insider transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-22
Item 8.01
Deep Fission completed a public offering of 2.5 million shares at $16.00 per share, generating $40 million in gross proceeds, with an additional 375,000-share greenshoe option granted to underwriters. While this is a registered public offering (not an unregistered private placement), it represents a material dilutive issuance of equity that would significantly affect a reasonable investor's assessment of ownership and capital structure, particularly for a newly public company (trading began June 18, 2026).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-22
Item 8.01
The Company issued 2,727,272 warrants to Maxim Group LLC as part of a settlement arrangement, with the warrants exercisable into common stock at $0.6325 per share. This represents a dilutive equity issuance to a placement agent in connection with the Company's at-the-market offering program. The warrant issuance, combined with the $1,050,000 cash fee and future 3% commission on ATM proceeds, constitutes material consideration for capital-raising services and would materially dilute existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 8.01
The Company completed an initial public offering of 5.5 million shares at $12.50 per share, generating approximately $68.75 million in gross proceeds. This material capital-raising event significantly affects the registrant's capitalization and ownership structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-22
RedHill Biopharma entered into a Securities Purchase Agreement on June 18, 2026, for a private placement of 8,571,429 ADSs (each representing 10,000 ordinary shares), Series A-1 and Series A-2 warrants, and pre-funded warrants at a combined purchase price of $0.70 per ADS and accompanying warrants. The offering is expected to generate approximately $6 million in gross proceeds, with potential additional proceeds of $13.4 million if warrants are fully exercised. This is a classic dilutive equity issuance to an accredited investor under Section 4(a)(2) and Regulation D, materially affecting shareholder ownership and voting rights.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-22
RedHill Biopharma announced the closing of a private placement of 8,571,429 ADSs at $0.70 per ADS with accompanying warrants, generating $6 million upfront with up to $13.4 million in potential proceeds from warrant exercises. This is an unregistered equity issuance under Section 4(a)(2) and Regulation D, representing a dilutive capital raise typical of small- and mid-cap biopharmaceutical companies. The company explicitly notes the securities "have not been registered under the Securities Act" and references a registration rights agreement for future resale registration, confirming the private placement structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-06-22
EX-99.1
NOVONIX is applying for quotation of 129,334,163 ordinary fully paid shares issued on 22 June 2026 at AUD 0.16 per share as part of a placement previously announced in an Appendix 3B dated 17 June 2026. This represents a significant equity issuance that dilutes existing shareholders and raises approximately AUD 20.7 million in cash consideration, materially affecting the capital structure and ownership percentages of existing investors.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 90%
filed 2026-06-22
EX-99.2
NOVONIX announced a Share Purchase Plan (SPP) offering eligible shareholders the opportunity to purchase up to A$30,000 of new fully paid ordinary shares at A$0.16 per share (a 33.3% discount to market), targeting to raise approximately A$3.0 million. This SPP follows a concurrent institutional placement that raised approximately A$20.7 million, together constituting a material dilutive equity issuance of approximately A$23.7 million.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-22
Item 8.01
Strategy Inc conducted an at-the-market (ATM) offering program, selling 2,714,839 shares of MSTR Stock and generating $335.5 million in net proceeds during the period, with a $21.0 billion MSTR Increase announced on March 23, 2026. ATM offerings are dilutive equity issuances that materially affect existing shareholders and represent significant capital-raising activity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Virgin Galactic is issuing shares of common stock and pre-funded warrants in exchange for approximately $52.5 million in principal amount of convertible notes. This is an unregistered equity issuance relying on Section 4(a)(2) of the Securities Act, issued to qualified institutional buyers and accredited investors. The transaction is material as it reduces debt by 75% while diluting existing shareholders through the issuance of new equity securities, and the company explicitly states the purpose is to "improve liquidity, manage its cash position and strengthen its balance sheet" ahead of commercial operations.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-22
EX-99.3
SOPHiA GENETICS completed a $57.5 million public offering of 12,104,900 ordinary shares at $4.75 per share, including 1,578,900 shares from full exercise of the underwriters' option. The offering was initially announced and priced at $50 million for 10,526,000 shares, with the underwriters' option fully exercised at closing.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
EQT Infrastructure Company LLC disclosed an unregistered sale of 6,381,666 equity shares across multiple classes for aggregate consideration of approximately $171.8 million as of June 1, 2026, exempt from Securities Act registration under Section 4(a)(2), Regulation D, and/or Regulation S. Since inception on February 1, 2026, the Company has sold approximately $711.5 million of such shares as part of a continuous private offering, representing a material capital raise affecting investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
EQT Private Equity Company LLC completed an unregistered sale of approximately $41.9 million in equity shares (1,449,986 shares across multiple classes) to third-party investors as of June 1, 2026, under Section 4(a)(2) and Regulations D and S. This private placement is part of a continuous offering that has raised approximately $788.3 million since inception.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
PennantPark Private Income Fund issued 110,906 common shares for approximately $2.864 million in an unregistered private offering relying on Section 4(a)(2) and Regulation D exemptions, diluting existing shareholders' ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Adaptive Biotechnologies issued $300 million of convertible senior notes in a private placement to qualified institutional buyers under Rule 144A, with up to 20,034,840 shares of common stock potentially issuable upon conversion, representing a dilutive unregistered equity issuance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Apollo Debt Solutions BDC sold 2,378,661 unregistered Class I Common Shares for $56.8 million to feeder vehicles, relying on Section 4(a)(2) and Regulation S exemptions from Securities Act registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-22
Item 3.02
Olenox issued $14 million in Series E Preferred Stock and warrants for 1.5 million common shares to the sellers of CS Digital as partial acquisition consideration, relying on Section 4(a)(2) and Rule 506(b) exemptions from registration.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-06-22
Nexera issued a $2,000,000 convertible promissory note (purchased for $1,800,000 cash) on June 18, 2026, together with a warrant to purchase 3,212,336 ordinary shares at $0.734 per share. The note is convertible at the holder's option at a variable price floor of $0.14680 per share, creating substantial dilution potential. This is a classic dilutive private placement of convertible debt and warrants, materially affecting shareholder equity and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-22
Item 3.02
Ondas Inc. issued unregistered equity securities to non-U.S. investors under Regulation S, increasing share count and diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-22
Item 8.01
Ondas Inc. registered 3,126,979 shares for resale by stockholders who acquired them as consideration in acquisitions of Omnisys Ltd. and World View Enterprises Inc., increasing share count and dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-22
Item 1.01
Pluri entered into an Advance Subscription Agreement on June 14, 2026, whereby Chutzpah Holdings LP (beneficially owned by board chairman Alexandre Weinstein) advanced $1.25 million to be credited toward the purchase of securities in a future financing to be consummated by August 14, 2026. This arrangement constitutes a dilutive equity issuance commitment.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-22
Item 1.01
Genvor Inc entered into a securities purchase agreement with Evergreen Capital Management on April 16, 2026, amended June 17, 2026, to issue convertible promissory notes (up to $800,000 principal) and warrants to purchase up to 1,200,000 shares of common stock for aggregate proceeds of up to $666,668. The warrant issuance was unregistered under Section 4(a)(2) of the Securities Act and includes a cashless exercise provision, representing a material dilutive equity capital raise.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-06-22
The Company announced a court petition to reduce the conversion price of Series D Convertible Debentures from NIS 165 to NIS 75.95 per share, which would increase convertible shares from 375,757 to 816,326 ordinary shares—a 117% increase in dilution. This is a material capital structure event that would substantially dilute existing shareholders upon conversion approval and NYSE American listing approval.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 8.01
CervoMed closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising $10 million in gross proceeds pursuant to an effective Form S-3 shelf registration statement. This registered equity issuance dilutes existing shareholders and is material given the company's disclosed going-concern risks and dependence on additional financing to advance its Phase 3 trial.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
This Item 3.02 disclosure reports unregistered sales of 1,881,554 shares of common stock issued between April 1 and June 17, 2026 through warrant exercises (both cash and cashless) and a warrant exchange agreement. The largest single transaction on 6/17/2026 involved the exchange of 2,362,279 warrants for 1,616,779 shares, representing substantial dilution to existing shareholders. The securities were issued in reliance on Section 4(a)(2) and Section 3(a)(9) exemptions, confirming unregistered issuance status typical of dilutive equity raises.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-22
The 6-K discloses a registered direct offering of 16,571,429 Class A ordinary shares at $0.35 per share for gross proceeds of $5.8 million, entered into on June 16, 2026. This is a dilutive equity issuance of registered securities under the company's effective Form F-3 shelf registration statement, material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-22
EX-99.1
InterCure announced a binding term sheet for a private placement of NIS 22 million (potentially NIS 54 million) involving issuance of 7,895,143 ordinary shares at NIS 2.75 per share plus warrants to purchase an additional 7,895,143 shares. This is an unregistered equity issuance raising capital, with the securities explicitly noted as not registered under the Securities Act of 1933. The participation of the CEO and leading pharma-focused hedge funds, combined with the material capital raise and dilutive warrant component, makes this a significant dilutive issuance material to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
The filing discloses a registered direct offering of 410,998 common shares at $7.056 per share, combined with a concurrent private placement of 410,998 unregistered warrants exercisable at the same price. The private placement of unregistered securities under Section 4(a)(2) and Regulation D, coupled with the aggregate gross proceeds of approximately $2.9 million, represents a classic dilutive equity issuance. Item 3.02 explicitly incorporates the unregistered securities disclosure, confirming this is the material event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-22
The filing discloses entry into an At-the-Market (ATM) Sales Agreement on June 22, 2026, under which Oxbridge Re Holdings Limited may offer and sell ordinary shares through Chardan Capital Markets LLC as sales agent. The agreement covers up to $1,678,301 in registered ordinary shares and represents a dilutive equity issuance mechanism. While ATM offerings are less immediately dilutive than a fixed-size PIPE, they create ongoing dilution risk and are material capital-raising activities, particularly for a small-cap reinsurer.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-22
Item 8.01
Allogene filed a prospectus supplement on June 22, 2026 authorizing sales of up to $135.0 million in common stock pursuant to an at-the-market (ATM) sales agreement with TD Securities, representing a material dilutive equity issuance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 93%
filed 2026-06-22
Item 3.02
Data I/O closed a $9 million private placement on June 17, 2026, issuing 869,840 shares of common stock, convertible debentures ($6.8 million principal at 4.0% annual interest, maturing in five years and convertible into Series B preferred stock), and warrants to purchase 1,080,000 shares. The unregistered securities sale represents a material capital raise with significant equity dilution to existing shareholders, including potential conversion of debentures into approximately 2.73 million common shares and warrant overhang.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
This Item 3.02 disclosure describes an unregistered private placement of preferred stock under Regulation D Rule 506(b) to accredited investors. The Company issued 208,797 shares of Series 2025 Preferred Stock during the period June 3–21, 2026, raising approximately $2.08 million in aggregate proceeds. As of the filing date, 11.9 million shares of this series were outstanding, indicating a substantial ongoing capital raise. This is a classic dilutive equity issuance material to investors assessing the registrant's capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Monroe Capital issued 1,222,087 shares of common stock at $9.77 per share for aggregate proceeds of $11.9 million pursuant to subscription agreements, with the sale exempt from registration under Section 4(a)(2) and Regulation D/S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Blue Owl Credit Income Corp. completed an unregistered private placement sale of 527,106 shares of Class I common stock for approximately $4.8 million, exempt under Section 4(a)(2) and Regulation S, to feeder vehicles created to hold the Company's Class I shares.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-06-22
Item 1.01
BuzzFeed entered into two share purchase agreements on June 17–18, 2026, selling 4,216,999 shares of Class A common stock (including 2,173,155 newly issued shares) at $1.44 per share for approximately $5.8 million in aggregate proceeds, pursuant to Section 4(a)(2) exemption from Securities Act registration. The transaction materially dilutes existing shareholders and raises capital at a modest valuation.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Barings Private Credit Corp completed an unregistered private placement of 585,012.268 shares of common stock for approximately $11.7 million pursuant to subscription agreements with investors, exempt under Section 4(a)(2) and Regulation D/S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Blue Owl Technology Income Corp. completed an unregistered private placement of 430,280 shares of Class I common stock for approximately $4.2 million, exempt under Section 4(a)(2) and Regulation S, diluting existing shareholders and raising capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-18
The filing discloses an At Market Issuance Sales Agreement dated April 1, 2025, with a prospectus supplement filed June 18, 2026, for the sale of common stock under an effective Form S-3 registration statement. This is a registered equity offering that could result in dilution to existing shareholders. While the filing itself is primarily a legal opinion submission (Item 8.01), the underlying transaction—an ATM offering—is a material capital-raising event typical of dilutive issuances.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-18
EX-99.1
The exhibit announces the closing of a non-brokered private placement in which Micromem issued 9,400,000 common shares and 9,400,000 warrants for gross proceeds of approximately C$235,000. This is an unregistered equity issuance exempt from U.S. Securities Act registration, characteristic of a dilutive private placement. The issuance materially increases share count and dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-18
Item 3.02
PTC Therapeutics completed a $550 million private placement of convertible senior notes with an initial conversion price of approximately $107.48 per share, sold to qualified institutional buyers under Section 4(a)(2) and Rule 144A. The company does not intend to register the resale of the notes or conversion shares, creating significant dilution potential to common shareholders. Net proceeds of $328.8 million are being used to repurchase $222.0 million in aggregate principal of existing convertible notes and for general corporate purposes.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 8.01
The filing discloses the full exercise of an over-allotment option on June 18, 2026, resulting in the sale of 116,667 additional shares of common stock at $4.33 per share for net proceeds of approximately $470,858. This represents a dilutive equity issuance that increases the company's share count and is material to investors assessing ownership dilution and capital structure changes.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 1.01
Epsilon Energy entered into an at-the-market (ATM) sales agreement with Roth Capital Partners authorizing the sale of up to $15 million in common shares. This is a dilutive equity issuance mechanism that allows the company to raise capital through registered offerings at prevailing market prices. The material nature of the $15 million authorization and the equity dilution to existing shareholders makes this a significant capital-raising event that would affect investor assessment of the company's financing strategy and shareholder ownership.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-18
EX-99.1
NetClass Technology Inc. has entered into a Technical Development Service Agreement with Bangyuan Liu to issue 2,800,000 ordinary shares as consideration for software development services over a one-year engagement, with issuance required by May 31, 2026.
View raw filing on EDGAR →